TAX 323 Essai Vermorken PF vs TPF en induction
Etude randomisée, prospective, patients entre 18 et 70 ans, stades III/IV sans métastase à distance
Docetaxel = Taxotere (Sanofi)
The median progression-free survival was 11.0 months in the TPF group and 8.2 months in the PF group (hazard ratio for disease progression or death in the TPF group, 0.72; P=0.007).
Treatment with TPF resulted in a reduction in the risk of death of 27% (P=0.02),
with a median overall survival of 18.8 months, as compared with 14.5 months in the PF group.
There were more grade 3 or 4 events of leukopenia and neutropenia in the TPF group and more grade 3 or 4 events of thrombocytopenia, nausea, vomiting, stomatitis, and hearing loss in the PF group.
The rates of death from toxic effects were 2.3% in the TPF group and 5.5% in the PF group
Jan B. Vermorken, M.D., Ph.D., Eva Remenar, M.D., Carla van Herpen, M.D., Ph.D., Thierry Gorlia, M.Sc., Ricard Mesia, M.D., Marian Degardin, M.D., John S. Stewart, M.D., Svetislav Jelic, M.D., Jan Betka, M.D., Joachim H. Preiss, M.D., Ph.D., Danielle van den Weyngaert, M.D., Ahmad Awada, M.D., Ph.D., Didier Cupissol, M.D., Heinz R. Kienzer, M.D., Augustin Rey, M.D., Isabelle Desaunois, M.Sc., Bernier, M.D., Ph.D., and Jean-Louis Lefebvre, M.D., for the EORTC 24971/TAX 323 Study Group*
N Engl J Med 2007; 357:1695-1704